The recent resignation of Peter Marks as the head of the FDA's Center for Biologics Evaluation and Research (CBER) marks a significant moment for the cell and gene therapy industry. His departure has sparked widespread discussion about the future direction of the regulatory landscape and its
Ivan Kairatov is a Biopharma expert, with deep knowledge of tech and innovation in the industry and experience in research and development. He joins us today to discuss Ori Biotech’s new Preferred Partner Network (PPN), the collaboration with various organizations, and the impacts on cell therapy
The recent announcement by Bayer AG and BlueRock Therapeutics LP marks a significant milestone in the development of cell therapies aimed at vision restoration. The FDA has granted Fast Track designation to OpCT-001, a stem cell therapy designed to treat primary photoreceptor diseases such as
The concept of using the body's own immune system to combat cancer, known as immunotherapy, has undergone significant evolution over the past decade. Initially deemed a novel approach for treating a limited patient demographic with advanced cancer types, immunotherapy now stands as a fundamental
Recent advancements in healthcare are uncovering surprising new uses for existing medications, and one prominent example is Ozempic (semaglutide). Originally hailed for its effectiveness in treating diabetes and aiding in weight loss, Ozempic is now being investigated for its potential to address
In the rapidly evolving landscape of biopharmaceutical manufacturing, capturing real-time data has become pivotal in optimizing bioreactor performance and producing high-quality products. Inline monitoring technologies are at the forefront of this transformation, offering real-time surveillance and
